SS-31 (Elamipretide): The Mitochondrial Peptide Targeting Cellular Energy
Peptide Guides

SS-31 (Elamipretide): The Mitochondrial Peptide Targeting Cellular Energy

A complete guide to SS-31 (elamipretide), the cardiolipin-targeting peptide studied for Barth syndrome, heart failure, and mitochondrial aging.

By PeptideRundown Team •
⚠️ Medical Disclaimer: This article is for educational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Peptide Guide · Mitochondria · Cellular Energy

SS-31 (Elamipretide): The Mitochondrial Peptide Targeting Cellular Energy

A synthetic tetrapeptide that crosses cell membranes, binds cardiolipin on the inner mitochondrial membrane, and restores the machinery that produces 90% of your body's ATP. FDA-approved for Barth syndrome. Under investigation for heart failure and aging.

Cardiolipin · Mitochondria FDA-Approved · Barth Syndrome Heart Failure · Aging Research
~640
Molecular Weight
(Daltons)
2024
FDA Approval
(Barth Syndrome)
5,000x
Mitochondrial
Concentration
3–4 hr
Plasma
Half-Life

Most peptides work on hormones, receptors, or signaling pathways outside the cell. SS-31 goes somewhere different.

It crosses the cell membrane and parks itself on the inner mitochondrial membrane, right where your cells generate energy. That makes it one of the most unusual peptides in clinical development.

What This Guide Covers

This is an educational breakdown of SS-31 (elamipretide), covering its mechanism of action, clinical trials, dosing protocols, and safety profile. It is not a recommendation to use SS-31. Consult a qualified healthcare provider before considering any peptide regimen.


SS-31 at a Glance

Compound Profile

SS-31 / Elamipretide

Sequence: D-Arg-Dmt-Lys-Phe-NH2  |  Type: Synthetic tetrapeptide (4 amino acids)  |  Molecular Weight: ~640 Da  |  Other Names: Elamipretide, Bendavia, MTP-131, Stelanir  |  Primary Target: Cardiolipin on inner mitochondrial membrane  |  Route: Subcutaneous injection  |  FDA Status: Approved for Barth syndrome (2024)

Unlike most peptides that bind extracellular receptors, SS-31 is cell-permeable. It concentrates inside mitochondria at roughly 1,000 to 5,000 times the extracellular concentration within minutes of administration.

For a deeper compound profile, visit PeptideArc.


How SS-31 Works

The mechanism is specific and well-characterized. SS-31 doesn't just "support mitochondrial health" in some vague way. It binds a single target with measurable downstream effects.

SS-31: Cardiolipin-Targeted Mitochondrial Rescue
Cardiolipin binding · Cristae stabilization · ETC optimization · ROS reduction
Cardiolipin BINDING TARGET SS-31 binds via electrostatic & hydrophobic forces ↓ Prevents oxidation of cardiolipin KEY OUTCOME Membrane integrity preserved Cristae STRUCTURAL Stabilizes inner membrane folds ↓ ETC supercomplexes assemble properly Proton gradient held KEY OUTCOME Efficient ATP production ETC ELECTRON TRANSPORT Complexes I, III, IV run more efficiently ↓ Fewer electron leaks Better O2 usage Higher ATP yield KEY OUTCOME ~90% of body's energy restored ROS OXIDATIVE STRESS Prevents excess ROS at the source ↓ Up to 45% less mitochondrial ROS Normal signaling kept KEY OUTCOME Less oxidative damage to cells

Cardiolipin Binding: The Core Mechanism

Cardiolipin is a phospholipid found almost exclusively on the inner mitochondrial membrane. It's essential for the electron transport chain, the process that generates roughly 90% of your body's ATP.

SS-31 binds directly to cardiolipin through electrostatic and hydrophobic interactions (Birk et al., 2013).

What Cardiolipin Does

Required for proper assembly of electron transport chain supercomplexes. Anchors cytochrome c. Maintains the proton gradient that drives ATP synthase. Involved in mitochondrial fission, fusion, and protein import.

What SS-31 Does to It

Stabilizes cristae structure. Optimizes electron transport through complexes I, III, and IV. Reduces electron leak that forms damaging reactive oxygen species. Prevents cardiolipin peroxidation.

Why Cardiolipin Matters

Cardiolipin isn't just another membrane component. It's structurally unique, with four fatty acid chains instead of the usual two.

FunctionRole of Cardiolipin
ATP productionRequired for proper assembly of ETC supercomplexes
ApoptosisAnchors cytochrome c; oxidized cardiolipin releases it, triggering cell death
Mitochondrial dynamicsInvolved in fission and fusion of mitochondria
Protein importFacilitates transport of proteins into the mitochondrial matrix
Membrane potentialMaintains the proton gradient that drives ATP synthase

When cardiolipin becomes oxidized or depleted, mitochondria start failing. This happens in aging, heart failure, neurodegenerative disease, and genetic conditions like Barth syndrome.

Key Finding

Age-related decline in cardiolipin content correlates directly with reduced mitochondrial function in heart, brain, and skeletal muscle tissue (Paradies et al., 2010).

Reducing Oxidative Stress (Without Being an Antioxidant)

This distinction matters. SS-31 is not a traditional antioxidant that scavenges free radicals after they form. Instead, it prevents excess ROS from being generated in the first place by keeping the electron transport chain running efficiently.

Think of it like fixing a leaky pipe rather than mopping up the water (Szeto, 2014).

Mechanism

Not a Scavenger, a Stabilizer

Reduces mitochondrial ROS production by up to 45% in preclinical models. Does not affect normal ROS signaling (important because some ROS serve as cellular signals). Protects against ischemia-reperfusion injury, the damage that occurs when blood flow returns after a blockage.


Barth Syndrome: The FDA-Approved Indication

Barth syndrome is a rare genetic disorder caused by mutations in the tafazzin (TAFAZZIN) gene. This gene encodes the enzyme responsible for remodeling cardiolipin into its mature form.

Without functional tafazzin, cardiolipin accumulates in abnormal forms. The result is severe mitochondrial dysfunction, primarily affecting the heart and skeletal muscle.

1 in 300K
Estimated
Prevalence
X-linked
Inheritance
Pattern
40 mg
Approved
Daily Dose
+29.2 m
Walk Test
Improvement

The TAZPOWER Trial

This was the pivotal trial that led to FDA approval.

ParameterDetail
Participants12 patients with genetically confirmed Barth syndrome
DesignRandomized, double-blind, placebo-controlled crossover
Duration12 weeks per treatment period
Dose40 mg subcutaneous daily
Primary endpoint6-minute walk test (6MWT)
OutcomeElamipretidePlacebo
6MWT improvement+20.6 meters-8.6 meters
Total distance walkedSignificant improvementNo change
Patient-reported fatigueImprovedNo change

The difference between drug and placebo was 29.2 meters on the 6-minute walk test. In a disease this severe, that's clinically meaningful (Thompson et al., 2021).

FDA Milestone

The FDA granted approval in January 2024 under the brand name Stelanir, making elamipretide the first and only approved treatment specifically targeting the underlying mitochondrial dysfunction in Barth syndrome.


Heart Failure Research

Heart failure is, at its core, an energy crisis. The failing heart can't produce enough ATP to pump effectively. Since SS-31 targets mitochondrial energy production, it was a logical candidate.

EMBRACE Trial (HFrEF)

The largest heart failure trial for elamipretide enrolled 71 patients with heart failure and reduced ejection fraction.

Endpoint4 mg40 mgPlacebo
LV end-systolic volumeImprovedImprovedNo change
Ejection fractionTrend toward improvementTrend toward improvementNo change
6MWTNo significant changeNo significant changeNo change

The results were mixed. Cardiac imaging showed structural improvements, but functional measures like the walk test didn't hit statistical significance (Butler et al., 2020).

Why the Mixed Results?

Short treatment duration (4 weeks may not reverse years of cardiac remodeling), small sample size (underpowered for modest effects), and patient heterogeneity (heart failure has many subtypes) all likely contributed.

Post-Hoc Insight

Post-hoc analyses suggested elamipretide was most effective in patients with the worst baseline mitochondrial function, hinting that patient selection could be critical for future trials.

Ischemia-Reperfusion Injury

When a blocked artery is reopened (as in a heart attack or bypass surgery), the sudden return of oxygenated blood paradoxically causes additional damage.

Preclinical studies showed SS-31 reduced infarct size by 50–60% when administered before reperfusion in animal models (Kloner et al., 2012). Human trials for this indication have been limited and results have not matched the dramatic preclinical findings.


Aging and Exercise Applications

This is where SS-31 research gets particularly interesting for the longevity community. Mitochondrial dysfunction is one of the hallmarks of aging, and SS-31 directly targets it.

Age-Related Mitochondrial Decline

What Goes Wrong With Age

Cardiolipin content decreases. ROS production increases, creating a vicious cycle of oxidative damage. Mitochondrial DNA mutations accumulate. Damaged mitochondria aren't cleared efficiently (impaired mitophagy).

What SS-31 Addresses

Directly protects and stabilizes cardiolipin. Reduces excess ROS production at the source. These are the first two problems on the list, and they're the ones that cascade into everything else.

Preclinical Aging Data

The animal data is striking.

StudyModelKey Finding
Siegel et al., 2013Aged mice (26 months)8 weeks reversed skeletal muscle mitochondrial decline
Campbell et al., 2019Aged miceRestored cardiac diastolic function to near-young levels
Sweetwyne et al., 2017Aged mice (24 months)Reversed kidney mitochondrial changes within 8 weeks

Sources: Siegel et al., 2013, Campbell et al., 2019, Sweetwyne et al., 2017.

Key Finding

In aged mice, 8 weeks of SS-31 treatment was sufficient to restore skeletal muscle energetics to levels seen in young animals. This was not just slowing decline. It was reversal.

Exercise Performance

In aged animals, SS-31 improved exercise tolerance, likely through enhanced mitochondrial ATP production in skeletal muscle. The peptide also reduced exercise-induced oxidative damage.

Aerobic Capacity

More efficient oxidative phosphorylation could mean higher VO2 output.

Recovery

Reduced exercise-induced mitochondrial damage may speed recovery between sessions.

Fatigue Resistance

Better ATP production in endurance activities could delay exhaustion.

No controlled human trials have examined SS-31 specifically for exercise performance in healthy individuals. These remain speculative applications.


Dosing Protocols

Important

These are research-based protocols, not medical prescriptions. The only approved dosing is for Barth syndrome under medical supervision. Always work with a qualified provider.

ParameterDetail
Approved dose (Barth syndrome)40 mg subcutaneous daily
Research doses (heart failure)4 mg or 40 mg subcutaneous daily
Research doses (other)0.01 to 0.25 mg/kg in various trials
RouteSubcutaneous injection
Half-lifeApproximately 3–4 hours
FrequencyOnce daily in most protocols

Reconstitution

SS-31 from research suppliers typically comes as a lyophilized powder. Standard reconstitution with bacteriostatic water applies.

Practical Notes

The short half-life is worth noting. Unlike peptides such as BPC-157 or semaglutide that are dosed less frequently, SS-31 appears to require daily administration for sustained mitochondrial effects.

Some research protocols have used twice-daily dosing to maintain more consistent tissue concentrations.


Side Effects and Safety

SS-31 has a generally favorable safety profile based on clinical trial data across multiple indications.

Side EffectFrequencyNotes
Injection site reactionsVery common (~30%)Redness, pain, itching at injection site
HeadacheCommonUsually mild and transient
FatigueOccasionalParadoxical given the mechanism; typically resolves
NauseaOccasionalLess common than with GLP-1 peptides
DizzinessUncommonMore reported at higher doses
Skin reactionsUncommonRash or urticaria in some patients
Contact urticariaRareReported in Barth syndrome trials
When to Stop

Severe injection site reactions (spreading redness, swelling, signs of infection), allergic reactions (difficulty breathing, facial swelling, widespread hives), or persistent worsening of symptoms. Consult your provider immediately.

For a broader overview, see our peptide side effects guide.


SS-31 vs. MOTS-c: Two Approaches to Mitochondrial Health

Both SS-31 and MOTS-c are called "mitochondrial peptides," but they work through completely different mechanisms.

FeatureSS-31 (Elamipretide)MOTS-c
OriginSynthetic (lab-designed)Endogenous (mitochondrial DNA)
TargetCardiolipin on inner membraneAMPK pathway, nuclear gene regulation
MechanismStabilizes electron transport chainActivates cellular energy sensor
Primary effectsRestores structure & ATP productionMetabolic regulation, insulin sensitivity
Clinical trialsMultiple phase 2/3, one FDA approvalVery early development
FDA statusApproved (Barth syndrome)Not approved
Best studied forHeart failure, genetic mitochondrial diseaseMetabolic syndrome, obesity, exercise
Half-life~3–4 hoursNot well characterized in humans
Bottom Line

SS-31 works from the inside out, physically stabilizing the machinery that makes ATP. MOTS-c works from the outside in, activating signaling pathways that tell cells to ramp up energy metabolism. They're complementary rather than competing approaches.

For structural mitochondrial damage (aging, genetic disease, ischemia), SS-31 has stronger evidence. For metabolic dysfunction and insulin resistance, MOTS-c may be more relevant.


Who Might Benefit

Strong Evidence

Barth Syndrome Patients

The only FDA-approved indication. Demonstrated clinical benefit in a controlled trial.

Moderate Evidence

Mitochondrial Myopathies

Conditions where impaired mitochondrial function drives muscle weakness.

Mixed Evidence

Heart Failure Patients

Particularly those with evidence of mitochondrial dysfunction as a primary driver.

Preclinical Only

Aging Adults

Strong animal data showing reversal of age-related mitochondrial changes. No human aging trials yet.

Important

Outside of Barth syndrome, all applications are investigational. Clinical evidence in healthy aging adults does not yet exist.


Legal Status and Availability

United States

FDA-approved for Barth syndrome (Stelanir). Investigational for all other uses.

European Union

Not approved. Orphan drug designation granted.

Australia

Not approved. Available through special access schemes.

Research Use

Available from peptide research suppliers. Quality and purity vary.

The Barth syndrome approval does not make SS-31 legally available for off-label use without a prescription. Check our peptide legality guide for full details.


Frequently Asked Questions

What does SS-31 actually do?
SS-31 binds to cardiolipin on the inner mitochondrial membrane, stabilizing the electron transport chain. This improves ATP production, reduces excessive reactive oxygen species, and protects mitochondria from oxidative damage. The net effect is better cellular energy production.
How quickly does SS-31 work?
SS-31 concentrates in mitochondria within minutes of injection. Measurable improvements in mitochondrial function have been observed within hours in preclinical models. But clinical benefits take longer. In the Barth syndrome trial, improvements in exercise capacity were measured over 12 weeks. For age-related decline, animal studies suggest 4 to 8 weeks of daily treatment to see meaningful changes.
Is SS-31 the same as elamipretide?
Yes. SS-31 is the research name, elamipretide is the clinical/pharmaceutical name, and Stelanir is the brand name. Bendavia and MTP-131 are older names for the same compound.
Can SS-31 reverse aging?
That's a strong claim, and the honest answer is: we don't know yet in humans. In aged mice, SS-31 reversed mitochondrial dysfunction in the heart, skeletal muscle, and kidneys. Whether that translates to measurable anti-aging effects in people remains to be proven. What it can do is target one specific hallmark of aging: mitochondrial dysfunction. It won't make you younger, but it may help your mitochondria function more like they did when you were younger.
Can I combine SS-31 with other peptides?
No clinical trials have examined SS-31 in combination with other peptides. Theoretically, combining it with MOTS-c could provide complementary mitochondrial support through different mechanisms. Some in the research community also combine it with NAD+ precursors like NMN or NR, though evidence for synergy is limited to speculation. Always discuss combinations with a qualified provider.
How is SS-31 different from CoQ10 or other mitochondrial supplements?
CoQ10 is a component of the electron transport chain and works as an electron carrier. SS-31 doesn't carry electrons. It stabilizes the structural environment where electron transport happens. Think of CoQ10 as adding oil to an engine. SS-31 is more like reinforcing the engine block itself. Also, oral CoQ10 has poor bioavailability and limited ability to reach mitochondria. SS-31 concentrates in mitochondria at thousandfold higher levels than plasma, making it far more targeted.
What does SS-31 treatment cost?
Stelanir (the approved Barth syndrome treatment) is priced as an orphan drug, meaning very expensive, likely in the range of tens of thousands of dollars annually. Research-grade SS-31 from peptide suppliers varies widely but is generally in the range of $50 to $150 per vial depending on quantity and supplier.
Does SS-31 need to be cycled?
There's no established cycling protocol for SS-31. In clinical trials, it was administered daily for weeks to months without tapering or cycling. The mechanism (structural stabilization of cardiolipin) doesn't involve receptor desensitization, so there's less theoretical reason to cycle compared to peptides that act on hormone receptors. That said, long-term safety data beyond clinical trials is limited.

The Bottom Line

Summary

SS-31 is one of the most precisely targeted peptides in existence. Rather than working through hormone receptors or broad signaling pathways, it goes directly to the inner mitochondrial membrane and stabilizes the machinery that produces cellular energy.

The FDA approval for Barth syndrome validated the mechanism. The heart failure data, while mixed, showed biological activity in the right direction. And the preclinical aging data is some of the most compelling evidence for any single intervention targeting mitochondrial decline.

The big question is whether the striking animal results will translate to meaningful benefits in aging humans. That data doesn't exist yet. But for a peptide that targets one of the most fundamental processes in cellular biology, SS-31 is worth watching closely.

Medical Disclaimer
This article is for educational and informational purposes only. It is not medical advice and should not be treated as such. SS-31 (elamipretide) is FDA-approved only for Barth syndrome under the brand name Stelanir. All other uses discussed in this article are investigational. Always consult a qualified healthcare provider before starting any peptide protocol. Never self-administer any compound without proper medical supervision.

References

Birk AV, et al. The mitochondria-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250–1261. PubMed
Paradies G, et al. Role of cardiolipin peroxidation and cytochrome c release in the decline of mitochondrial function in aging. Free Radic Biol Med. 2010;48(10):1286–1295. PubMed
Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029–2050. PubMed
Thompson R, et al. Elamipretide in patients with Barth syndrome: a randomized, double-blind, placebo-controlled clinical trial followed by open-label extension. Genet Med. 2021;23(12):2364–2371. PubMed
Butler J, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: the EMBRACE trial. Eur J Heart Fail. 2020;22(3):431–441. PubMed
Kloner RA, et al. Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective peptide. J Am Heart Assoc. 2012;1(3):e001644. PubMed
Siegel MP, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013;12(5):763–771. PubMed
Campbell MD, et al. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radic Biol Med. 2019;134:268–281. PubMed
Sweetwyne MT, et al. The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age. Kidney Int. 2017;91(5):1126–1145. PubMed

Related reading:

What Are Peptides? Beginner's Guide  ·  Peptide Side Effects: What to Know  ·  Are Peptides Legal? FDA Regulations 2026  ·  MOTS-c Mitochondrial Peptide Guide

For compound profiles and sourcing info, visit PeptideArc.